Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Bayer Aktiengesellschaft, Bayer Aktiengesellschaft or Eli Lilly and Company because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Eli Lilly and Company compare based on key financial metrics to determine which better meets your investment needs.

About Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Eli Lilly and Company

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin’s lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer’s disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Latest Pharmaceuticals and Bayer Aktiengesellschaft, Bayer Aktiengesellschaft Stock News

As of September 2, 2026, Bayer Aktiengesellschaft had a $56.0 billion market capitalization, compared to the Pharmaceuticals median of $674.0 million. Bayer Aktiengesellschaft’s stock is up 33.5% in 2026, up 2.3% in the previous five trading days and up 77.75% in the past year.

Currently, Bayer Aktiengesellschaft does not have a price-earnings ratio. Bayer Aktiengesellschaft’s trailing 12-month revenue is $51.8 billion with a -3.8% net profit margin. As of September 2, 2026, Bayer Aktiengesellschaft has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $1.297 per share for the current fiscal year. Bayer Aktiengesellschaft does not currently pay a dividend.

As of September 2, 2026, Bayer Aktiengesellschaft had a $56.0 billion market cap, putting it in the 94th percentile of all stocks. Bayer Aktiengesellschaft’s stock is up 33.5% in 2026, up 2.3% in the previous five trading days and up 77.75% in the past year.

Currently, Bayer Aktiengesellschaft does not have a price-earnings ratio. Bayer Aktiengesellschaft’s trailing 12-month revenue is $51.8 billion with a -3.8% net profit margin. As of September 2, 2026, Bayer Aktiengesellschaft has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $1.297 per share for the current fiscal year. Bayer Aktiengesellschaft does not currently pay a dividend.

How We Compare Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Eli Lilly and Company Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Eli Lilly and Company’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Eli Lilly and Company’s Quality Grades

Company	Ticker	Quality
Bayer Aktiengesellschaft	BAYRY	B
Bayer Aktiengesellschaft	BAYRY	B
Eli Lilly and Company	LLY	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Bayer Aktiengesellschaft has a Quality Score of 73, which is Strong. Bayer Aktiengesellschaft has a Quality Score of 73, which is Strong. Eli Lilly and Company has a Quality Score of 90, which is Very Strong.

The Quality Grade Winner: It’s a Tie!

Looking at the Quality Grade breakdown above, both Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Eli Lilly and Company have a grade of B. For investors who focus solely on a company’s overall quality, you will need to conduct further research into both companies to see if they are a good fit for your portfolio. As a good rule of thumb, you should always analyze multiple factors based on a wide range of metrics before choosing a company to invest in.

Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Eli Lilly and Company’s Momentum Grades

Company	Ticker	Momentum
Bayer Aktiengesellschaft	BAYRY	A
Bayer Aktiengesellschaft	BAYRY	A
Eli Lilly and Company	LLY	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Bayer Aktiengesellschaft has a Momentum Score of 90, which is Very Strong. Bayer Aktiengesellschaft has a Momentum Score of 90, which is Very Strong. Eli Lilly and Company has a Momentum Score of 75, which is Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Eli Lilly and Company have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Eli Lilly and Company’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Bayer Aktiengesellschaft	BAYRY	F
Bayer Aktiengesellschaft	BAYRY	F
Eli Lilly and Company	LLY	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Bayer Aktiengesellschaft has a Earnings Estimate Score of 5, which is Very Negative. Bayer Aktiengesellschaft has a Earnings Estimate Score of 5, which is Very Negative. Eli Lilly and Company has a Earnings Estimate Score of 63, which is Positive.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Bayer Aktiengesellschaft, Bayer Aktiengesellschaft or Eli Lilly and Company has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Bayer Aktiengesellschaft, Bayer Aktiengesellschaft or Eli Lilly and Company is the better investment when it comes to estimate revisions.

Other Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Eli Lilly and Company Grades

In addition to Momentum, Estimate Revisions and Quality, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Eli Lilly and Company pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Bayer Aktiengesellschaft, Bayer Aktiengesellschaft or Eli Lilly and Company Stock?

Overall, Bayer Aktiengesellschaft stock has a Momentum Score of 90, Estimate Revisions Score of 5 and Quality Score of 73.

Bayer Aktiengesellschaft stock has a Momentum Score of 90, Estimate Revisions Score of 5 and Quality Score of 73.

Eli Lilly and Company stock has a Momentum Score of 75, Estimate Revisions Score of 63 and Quality Score of 90.

Comparing Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Eli Lilly and Company’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.